Humacyte, Inc.
HUMAHealthcareNASDAQBiotechnology · Last scanned Sep 3, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of Sep 2
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions. At a $165.7M market cap, Humacyte, Inc. ranks as a micro-cap company within healthcare. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Market Cap
$165.7M
Beta
2.47
P/E (TTM)
—
P/E (Fwd)
-2.41
EPS (TTM)
$-0.54
EPS (Fwd)
$-0.25
ROE
-547.9%
ROA
-49.9%
Cash
$79.9M
Total Debt
$66.9M
Free CF
-$58.4M
52W Change
-61.0%
Annual Financials
Cash vs Debt
Where HUMA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, HUMA finished 31.82% below its 150-day moving average ($0.88) and 36.84% below its 200-day moving average ($0.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HUMA overbought or oversold?
At the September 3, 2026 close, HUMA's RSI(14) was 53.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $79.9M in cash comfortably exceeding the $66.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$58.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -547.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Humacyte, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Humacyte, Inc. and its sector.